Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript

Quanterix (QTRX) reported Q2 2025 revenue of $24.5 million, a 29% year-over-year decline, falling short of expectations due to temporary headwinds in academic funding and biopharma spending, resulting in a -$13.7 million adjusted EBITDA loss. Despite these challenges, the company completed its transformative Akoya acquisition in July, which expands its addressable market to $5 billion across neurology, immunology, and oncology. Management is aggressively pursuing cost reductions, targeting $85 million in annualized savings by 2026 (75% already implemented), and remains committed to achieving cash flow positivity in 2026, with the combined company guiding for $130 million to $135 million in revenue for 2025. Strategic initiatives, including the upcoming launch of Simoa One and development of its Alzheimer's diagnostic franchise, leverage its leadership in high-sensitivity proteomics for long-term growth.

Analysis

Quanterix reported a challenging second quarter with revenue declining 29% year-over-year to $24.5 million, significantly missing expectations due to market-wide headwinds in academic and biopharma spending. The weakness was broad-based, with academic sales down 18%, pharma sales down 38%, and Accelerator Lab revenue declining 60%. In response, management is executing a significant strategic pivot centered on the post-quarter acquisition of Akoya, which expands the company's total addressable market to $5 billion and diversifies its revenue stream, with immunology and oncology now representing 47% of the pro forma mix. To navigate the current macro environment and fund this new strategy, the company has increased its cost-saving and synergy target to $85 million by 2026, with 75% of these reductions already implemented on a run-rate basis. This aggressive cost discipline underpins the reiterated commitment to achieving cash flow positivity in 2026, despite the near-term revenue pressures. The forward-looking strategy is supported by a solid pro forma consumables revenue base of approximately $100 million, the upcoming launch of the next-generation Simoa One platform, and tangible progress in the high-potential Alzheimer's diagnostic franchise, which saw revenues triple. The company guides for full-year 2025 combined revenue of $130 million to $135 million, establishing a new performance baseline for the integrated entity.

Key Decisions for Investors

• The investment thesis now hinges on execution, so investors should prioritize monitoring the quarterly realization of the targeted $85 million in cost synergies and progress toward the stated 2026 cash flow breakeven goal.
• Expect continued share price volatility as the market balances severe near-term revenue headwinds against the long-term growth potential unlocked by the Akoya acquisition and future product cycles like the Simoa One platform.
• Look beyond headline revenue to leading indicators such as the stability of the pro forma $100 million consumables business and critical milestones in the Alzheimer's franchise, particularly the anticipated Medicare pricing recommendation, as signals of a successful turnaround.
• Given the significant drop in instrument placements and large-project revenue, investors should be cautious about the pace of recovery in capital spending and consider the resilient consumables franchise as the primary near-term value driver.